Temozolomide in resistant or relapsed pediatric solid tumors

L. De Sio, G. M. Milano, A. Castellano, A. Jenkner, P. Fidani, C. Dominici, A. Donfrancesco

Research output: Contribution to journalArticlepeer-review


Purpose. We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors. The drug was administered at the dose of 215 mg/m2/day × 5 days or 180 mg/m2/day × 5 days in patients with prior craniospinal irradiation (CSI) or autologous bone marrow transplantation (ABMT). Patients and Methods. Fifty two patients, median age 127.6 months, with resistant or relapsed solid tumors were enrolled. Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1). All patients were pre-treated. Two outpatient courses were administered, with a median of 4.8 courses/pt. Results. Objective response-rate (CR + PR + MR) in our series was 13.4% (1.9% CR, 3.8% PR, and 7.7% MR), SD occurred in 38.4% of patients and 48% had PD. The median survival was 7.8 months (range 1-37) and median time to progression was 3.4 months (range 1-20); these data were significantly correlated with histology and previous nitrosureas administration in multivariate analysis. Haematological toxicity grade 3-4 (mainly thrombocytopenia) was observed in 21.4% of administered courses, nausea was reported in 3.1% and respiratory distress in 0.7%. Conclusion. Oral TMZ was well tolerated in children with resistant or relapsed solid tumors and showed activity in NB and CNS tumours refractory to standard chemotherapy.

Original languageEnglish
Pages (from-to)30-36
Number of pages7
JournalPediatric Blood and Cancer
Issue number1
Publication statusPublished - Jul 2006


  • Chemotherapy
  • Pediatric oncology
  • Solid
  • Tumors

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Temozolomide in resistant or relapsed pediatric solid tumors'. Together they form a unique fingerprint.

Cite this